Fig. 3. Monoallelic TNFRSF17 deletion coupled with p.Arg27Pro mutation in the extracellular domain of BCMA mediates MM relapse after anti-BCMA TCE therapy in patient MM-3.

a, Pre-therapy versus post-relapse CD138⁺ MM cell BCMA protein expression by flow cytometry using monoclonal anti-BCMA antibody (clone 19F2). b, Pre-therapy versus post-relapse CD138⁺ BCMA protein expression level by flow cytometry using polyclonal anti-BCMA antibody. c, ScCNV-seq heatmap comparing the CN changes in chromosomes 1–22 in pre-therapy (pre) versus post-relapse (post) CD138⁺ MM cells. d, Pre-therapy and post-relapse CD138⁺ CN alteration at the TNFRSF17 locus based on scCNV-seq. The barplot and table compare the percentages of cells harboring the CNVs in pre- versus post-CAR T/TCE relapse samples. e, Lollipop plot illustrating the 11965404G>C mutation in exon 1 of the TNFRSF17 gene. Integrated Genomics Viewer (IGV) screenshot illustrating newly detected clonal point mutation in post-relapse CD138⁺ MM cells. f, Fish plot of clonal phylogeny of the CD138⁺ cells at pre-therapy versus post-relapse timepoints inferred from scCNV-seq data. The associated phylogenetic tree illustrates the main alterations differentiating each clone.